Turenne Capital-backed Banook Group completed the acquisition of Nabios.

Turenne Capital-backed Banook Group, a global provider of cardiac, imaging and endpoint adjudication central services to the pharmaceutical, biotechnology and medical sectors, completed the acquisition of Nabios, a German company that specialises in cardiac safety assessments in clinical trials of drugs intended for human health. Financial terms were not disclosed. "We shared many common values with Nabios GmbH and we felt there was a real opportunity to start a partnership. Moreover, we were both facing a consolidation of the CRO market, which resulted in a demand for alternatives for clients. The alliance of our two structures, Banook and Nabios GmbH, will allow us to strengthen our geographical presence in Europe with clients in our respective geographical territories including France for Banook and Germany for Nabios GmbH,) and in complementary geographies such as Northern Europe," Alexandre Durand-Salmon, Banook Group CEO.